LumiraDx Investor Presentation Deck
125
100
75
50
25
Our Extended Portfolio Targets the Global IVD
Market Across Sectors
We have been able to leverage our technology and manufacturing
expertise to directly serve the lab and self-testing segments
LumiraDx Targets the Global IVD Market ($B)
Platform Focus
12
POC Professional
Testing
lumiraDx™
RNA Star Lab Test
64
Central Lab
28
Amira Self Test
COVID
13
Source: Industry reports, companyestimates
Self Testing
117
Total
Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide
Commentary
LumiraDx has developed a unique
offering capable addressing the
global IVD market:
The Platform
i. improves POC
professional testing, and
ii. will allow transition of
some lab-based test to
the point of care
The RNA Star Lab Test
improves PCR speed and
efficiency for Central Lab test
The Amira System leverages
the technology of our Platform
to serve the Self Testing
segment
38View entire presentation